References

References:

  1. Akgul M, MacLennan GT, Cheng L. The applicability and utility of immunohistochemical biomarkers in bladder pathology. Hum Pathol. 2020;98:32-55.
  2. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32(3):377-382.
  3. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology. 2000;36(1):32-40.
  4. Carlo MI, Chaim J, Patil S, et al. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clin Genitourin Cancer. 2017;15(6):e987-e994.
  5. Classe M, Malouf GG, Su X, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70(7):1089-1097.
  6. Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol. 1998;29(12):1451-1456.
  7. Grosser D, Matoso A, Epstein JI. Clear Cell Adenocarcinoma in Men: A Series of 15 Cases. Am J Surg Pathol. 2021;45(2):270-276.
  8. Jager L, Morency EG, Choy B. Malignant Cells in Urine Cytology: Not Always High-Grade Urothelial Carcinoma. AJSP: Reviews and Reports. 2022;27(3):132-134.
  9. Kobayashi N, Matsuzaki O, Shirai S, Aoki I, Yao M, Nagashima Y. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39(9):1350-1359.
  10. Layfield LJ, Elsheikh TM, Fili A, Nayar R, Shidham V; Papanicolaou Society of Cytopathology. Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting: the Papanicolaou Society of Cytopathology Practice Guidelines Task Force. Diagn Cytopathol. 2004;30(1):24-30.
  11. Li Y, Ding YU, Chen D, et al. Renal cell carcinoma growing into the renal pelvis and mimicking transitional cell carcinoma: A case report and literature review. Oncol Lett. 2015;9(4):1869-1872.
  12. Ng JKM, Li JJX. Cytomorphologic comparison of upper urinary tract urothelial carcinomas and renal cell carcinomas on urine cytology. Diagn Cytopathol. 2024;52(11):671-678.
  13. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726-4734.
  14. Reuter VE, Argani P, Zhou M, Delahunt B; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e35-e49.
  15. Rosenthal DL, Wojcik EM, Kurtycz DFI. The Paris System for Reporting Urinary Cytology. 2nd edition. Cham, Switzerland: Springer; 2022. Sanguedolce F, Loizzi D, Sollitto F, et al. Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. Oncology. 2017;92(3):125-134.
  16. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19(4):293-299.
  17. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648.
  18. Xiao GQ, Chow J, Unger PD. Metastatic tumors to the urinary bladder: clinicopathologic study of 11 cases. Int J Surg Pathol. 2012;20(4):342-348.